Heidelberger C (1975) Fluorinated pyrimidines and their nucleosides. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents. Handbook of experimental Pharmacology. Springer, Berlin, pp 193–231

Chapter  Google Scholar 

Haller DG, Tabernero J, Maroun J et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465–1471. https://doi.org/10.1200/JCO.2010.33.6297

Article  CAS  PubMed  Google Scholar 

Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338. https://doi.org/10.1038/nrc1074

Article  CAS  PubMed  Google Scholar 

Sauer R, Becker H, Hohenberger W Preoperative versus postoperative Chemoradiotherapy for Rectal Cancer., Engl N J Med Overseas 351:1731–1740., Bosset J-F, Collette L, Calais G et al (2004) (2006): Chemotherapy with preoperative radiotherapy in rectal cancer. N Eng J Med 355:1114–1123. https://doi.org/10.1056/NEJMoa060829

Gérard J-P, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625. https://doi.org/10.1200/JCO.2006.06.7629

Article  PubMed  Google Scholar 

Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30:1926–1933. https://doi.org/10.1200/JCO.2011.40.1836

Article  CAS  PubMed  Google Scholar 

Rödel C, Liersch T, Becker H et al (2012) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13:679–687. https://doi.org/10.1016/S1470-2045(12)70187-0

Article  CAS  PubMed  Google Scholar 

Rödel C, Graeven U, Fietkau R et al (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16:979–989. https://doi.org/10.1016/S1470-2045(15)00159-X

Article  CAS  PubMed  Google Scholar 

Schmoll H-J, Stein A, van Cutsem E et al (2021) Pre- and postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. J Clin Oncol 39:17–29. https://doi.org/10.1200/JCO.20.01740

Article  CAS  PubMed  Google Scholar 

André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116. https://doi.org/10.1200/JCO.2008.20.6771

Article  CAS  PubMed  Google Scholar 

André T, de Gramont A, Vernerey D et al (2015) Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 33:4176–4187. https://doi.org/10.1200/JCO.2015.63.4238

Article  CAS  PubMed  Google Scholar 

Hofheinz R-D, Arnold D, Fokas E et al (2018) Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial. Ann Oncol 29:1793–1799. https://doi.org/10.1093/annonc/mdy205

Article  CAS  PubMed  Google Scholar 

Fokas E, Allgäuer M, Polat B et al (2019) Randomized phase II trial of chemoradiotherapy plus induction or consolidation ccemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol 37:3212–3222. https://doi.org/10.1200/JCO.19.00308

Article  CAS  PubMed  Google Scholar 

van der Valk MJM, Marijnen CAM, van Etten B et al (2020) Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer– Results of the international randomized RAPIDO-trial. Clin Transl Radiat Oncol 147:75–83. https://doi.org/10.1016/j.radonc.2020.03.011

Article  CAS  Google Scholar 

Conroy T, Bosset J-F, Etienne P-L et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22:702–715. https://doi.org/10.1016/S1470-2045(21)00079-6

Article  CAS  PubMed  Google Scholar 

Trotti A, Colevas A, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181. https://doi.org/10.1016/S1053-4296(03)00031-6

Article  PubMed  Google Scholar 

Grothey A, Sobrero AF, Shields AF et al (2018) Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med Overseas Ed 378:1177–1188. https://doi.org/10.1056/nejmoa1713709

Article  CAS  Google Scholar 

Sharma BB, Rai K, Blunt H et al (2021) Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: A systematic review and meta-analysis. Oncologist 26:1008–1016. https://doi.org/10.1002/onco.13967

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guellec B-L, Lafay-Chebassier C, Ingrand C I, et al (2020) Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France. Eur J Cancer 124:37–46. https://doi.org/10.1016/j.ejca.2019.09.028

Article  CAS  Google Scholar 

van Kuilenburg ABP (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939–950. https://doi.org/10.1016/j.ejca.2003.12.004

Article  CAS  PubMed  Google Scholar 

Pallet N, Hamdane S, Garinet S et al (2020) A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency. Br J Cancer 123:811–818. https://doi.org/10.1038/s41416-020-0962-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

European Medicines Agency (2020) EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. https://www.ema.europa.eu/en/news/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine. Reference Number: EMA/229267/2020. Accessed 12 December 2024

Terrazzino S, Cargnin S, Del Re M et al (2013) DPYD IVS14 + 1G > A and 2846A > T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 14:1255–1272. https://doi.org/10.2217/pgs.13.116

Article  CAS  PubMed  Google Scholar 

Rosmarin D, Palles C, Church D et al (2014) Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-Analysis. J Clin Oncol 32:1031–1039. https://doi.org/10.1200/JCO.2013.51.1857

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meulendijks D, Henricks LM, Sonke GS et al (2015) Clinical relevance of DPYD variants c.1679T > G, c.1236G > A/HapB3, and c.1601G > A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16:1639–1650. https://doi.org/10.1016/S1470-2045(15)00286-7

Article  CAS  PubMed  Google Scholar 

Lunenburg CATC, Henricks LM, Guchelaar H-J et al (2016) Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time. Eur J Cancer 54:40–48. https://doi.org/10.1016/j.ejca.2015.11.008

Article  PubMed  Google Scholar 

Wittekind C, Brierley JD, Lee A, van Eycken E (2019) TNM supplement: a commentary on uniform use. Wiley

Brierley J, Gospodarowicz MK, Wittekind C (2017) International union against cancer. TNM classification of malignant tumours. Wiley Blackwell, Oxford

Google Scholar 

R Core Team (2023) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. https://www.R-project.org. Accessed 12 December 2024

Bates D, Mächler M, Bolker BM, Walker SC (2015) Fitting linear mixed-effects models using lme4. J Stat Softw 67:1–48. https://doi.org/10.18637/jss.v067.i01

Article  Google Scholar 

Froehlich TK, Amstutz U, Aebi S et al (2014) Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer 136:730–739. https://doi.org/10.1002/ijc.29025

Article  CAS  PubMed  Google Scholar 

Amstutz U, Henricks LM, Offer SM et al (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103:210–216. https://doi.org/10.1002/cpt.911